Database Queries
Through its patient testing, Monogram has built an extensive library of viruses from which it has generated robust resistance characterization data that are available to pharmaceutical clients. Clients can query Monogram’s database to ask questions about prevalence of mutational patterns, genotypic/phenotypic correlates (by specific mutational pattern), as well as replication capacity (RC). These data can be useful not only in early stage drug development efforts, but in post-marketing efforts as well.
Monogram’s database contains the following:
Phenotypes: >232,000
Genotypes: >184,000
Matched phenotypes and genotypes: >125,000
Tropism (Trofile®): >62,000
Posters & Publications
Below are links to posters and presentations that include presented data to demonstrate our portfolio of Oncology VeraTag® assays, and also data from Monogram posters and abstracts featuring clinical studies where the Monogram database was utilized.
Grant RM, Hecht FM, Warmerdam M, et al. Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons. JAMA. 2002;288(2):181–188. doi:10.1001/jama.288.2.181
Gunst, J.D., Pahus, M.H., Rosás-Umbert, M. et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. Nat Med 28, 2424–2435 (2022). https://doi.org/10.1038/s41591-022-02023-7
Brochu, H.N., Song, K., Zhang, Q. et al. A program for real-time surveillance of SARS-CoV-2 genetics. Sci Rep 14, 20249 (2024). https://doi.org/10.1038/s41598-024-70697-9
Ellis, R.J., Chenna, A., Petropoulos, C.J. et al. Higher cerebrospinal fluid biomarkers of neuronal injury in HIV-associated neurocognitive impairment. J. Neurovirol. 28, 438–445 (2022). https://doi.org/10.1007/s13365-022-01081-4
Little SJ, Daar ES, D'Aquila RT, et al. Reduced Antiretroviral Drug Susceptibility Among Patients With Primary HIV Infection. JAMA. 1999;282(12):1142–1149. doi:10.1001/jama.282.12.1142
Su Y, Yuan D, Chen DG, et al. Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. Cell 185(5), 881-895 (2022). DOI: 10.1016/j.cell.2022.01.014
Sebastian Bonhoeffer et al. ,Evidence for Positive Epistasis in HIV-1.Science306,1547-1550(2004).DOI:10.1126/science.1101786
Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet. 2005;365(9464):1031-1038. doi:10.1016/S0140-6736(05)71139-9
Deeks S.G., Wrin T., Liegler T., Hoh R., Hayden M., Barbour J.D., et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 2001; 344(7): 472–80. https://doi.org/10.1056/nejm200102153440702
Tebas P, Lynn K, Azzoni L, et al. Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons. AIDS. 2023;37(8):1203-1207. doi:10.1097/QAD.0000000000003575
Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
N. Engl. J. Med. 1998; 339:307-311
Susceptibility to anti-HIV bnAbs is concordant in pre-ART plasma and on-ART PBMC samples Jacqueline Reeves, Yu Zheng, Maxine Olefsky, Yolanda Lie, Leah Burke, Babafemi Taiwo, Christos Petropoulos, Pablo Tebas, Marina Caskey, and Katharine Bar. ACTG NWCS413, 2019.
Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing Regimens. JAMA. 2000;283(2):229–234. doi:10.1001/jama.283.2.229
Walker, L., Huber, M., Doores, K. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466–470 (2011). https://doi.org/10.1038/nature10373
Chhabra A, Bashirians G, Petropoulos CJ. et al. Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies. Molecular Therapy Methods & Clinical Development. 2024. Vol. 32(3):1-11. DOI: 10.1016/j.omtm.2024.101273
Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al.. Antiretroviral-Drug Resistance among Patients Recently Infected with HIV. N Engl J Med. 2002. Vol. 347(6):385–394
Ronald J Ellis, Ahmed Chenna, Yolanda Lie, Dusica Curanovic, John Winslow, Bin Tang, Christina M Marra, Leah H Rubin, David B Clifford, J Allen McCutchan, Benjamin B Gelman, Jessica Robinson-Papp, Christos J Petropoulos, Scott L Letendre, Higher Levels of Cerebrospinal Fluid and Plasma Neurofilament Light in Human Immunodeficiency Virus-Associated Distal Sensory Polyneuropathy, Clinical Infectious Diseases, Volume 76, Issue 6, 15 March 2023, Pages 1103–1109, https://doi.org/10.1093/cid/ciac851
Peluso M, Deitchman AN, Torres L, et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Reports. 2021. Vol. 36(6):1-14. DOI: 10.1016/j.celrep.2021.109518
Boden D, Hurley A, Zhang L, et al. HIV-1 Drug Resistance in Newly Infected Individuals. JAMA. 1999;282(12):1135–1141. doi:10.1001/jama.282.12.1135
Laura M. Walker et al. ,Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target.Science326,285-289(2009).DOI:10.1126/science.1178746
Gunst, J.D., Pahus, M.H., Rosás-Umbert, M. et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. Nat Med 28, 2424–2435 (2022). https://doi.org/10.1038/s41591-022-02023-7
Hinkley, T., Martins, J., Chappey, C. et al. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat Genet 43, 487–489 (2011). https://doi.org/10.1038/ng.795